Gender differences in regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy

Hypertension

Volumn 52, Issue 1, 2008, Pages 100-106

  Okin, Peter M ^a,h   Gerdts, Eva ^b,c   Kjeldsen, Sverre E ^d,e   Julius, Stevo ^e   Edelman, Jonathan M ^f   Dahlöf, Björn ^g   Devereux, Richard B ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF BERGEN   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

^g SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^h WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

Electrocardiography; Gender; Hypertension; Hypertrophy

Indexed keywords

ATENOLOL; HYDROCHLOROTHIAZIDE; LOSARTAN; PLACEBO; ANTIHYPERTENSIVE AGENT;

ADD ON THERAPY; ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; ELECTRIC POTENTIAL; ELECTROCARDIOGRAPHY; ESSENTIAL HYPERTENSION; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REMISSION; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; BLOOD FLOW VELOCITY; BLOOD PRESSURE; CHRONIC KIDNEY FAILURE; DOPPLER ECHOCARDIOGRAPHY; ECHOGRAPHY; GLOMERULUS FILTRATION RATE; MIDDLE AGED; MITRAL VALVE; MORTALITY; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PROGNOSIS; PROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD FLOW VELOCITY; BLOOD PRESSURE; ECHOCARDIOGRAPHY, DOPPLER; ELECTROCARDIOGRAPHY; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MITRAL VALVE; MULTIVARIATE ANALYSIS; PROGNOSIS; PROSPECTIVE STUDIES; SEX FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 46449133634     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.108.110064     Document Type: Article

References (38)

1. Levy D, Bailey JJ, Garrison RJ, Horton MR, Bak SM, Lyons D, Castelli WP. Electrocardiographic changes with advancing age: a cross-sectional study of the association of age with QRS axis, duration and voltage. J Electrocardiol. 1987;20(suppl):44-47.
2. Chen CY, Chiang BN, Macfarlane PW. Normal limits of the electrocardiogram in a Chinese population. J Electrocardiol. 1989;22:1-15.
3. Goldberger AL, Bhargava V. QRS duration measurement using high-frequency electrocardiography: applications and limitations of a new technique. Comput Biomed Res. 1982;15:474-484.
4. Simonson E, Blackburn H, Puchner TC, Eisenberg P, Ribeiro F, Meja M. Sex differences in the electrocardiogram. Circulation. 1960;22:598-601.
5. Okin PM, Roman MJ, Devereux RB, Kligfield P. Gender differences and the electrocardiogram in left ventricular hypertrophy. Hypertension. 1995;25:242-249.
6. Ostrander LD, Brandt RL, Kjelsberg MO, Epstein FH. Electrocardio-graphic findings among the adult population of a total natural community, Tecumseh, Michigan. Circulation. 1965;31:888-898.
7. Sotobata I, Richman H, Simonson E. Sex differences in the vectorcar-diogram. Circulation. 1968;37:438-448.
8. Siegel RJ, Roberts WC. Electrocardiographic observations in severe aortic stenosis: correlative necropsy study to clinical, hemodynamic, and ECG variables demonstrating relation of 12-lead QRS amplitude to peak systolic transaortic pressure gradient. Am Heart J. 1982;103:210-221.
9. Casale PN, Devereux RB, Kligfield P, Eisenberg RR, Miller DH, Chaudhary BS, Phillips MC. Electrocardiographic detection of left ventricular hypertrophy: development and prospective validation of improved criteria. J Am Coll Cardiol. 1985;6:572-580.
10. Alfakih K, Walters K, Jones T, Ridgway J, Hall AS, Sivananthan M. New gender-specific partition values for ECG criteria of left ventricular hypertrophy: recalibration against cardiac MRI. Hypertension. 2004;44: 175-179.
11. Mathew J, Sleight P, Lonn E, Johnstone D, Pogue J, Yi Q, Bosch J, Sussex B, Probstfield J, Yusuf S. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation. 2001;104:1615-1621.
12. Schlaich MP, Schmieder RE. Left ventricular hypertrophy and its regression: pathophysiology and therapeutic approach: focus on treatment by antihypertensive agents. Am J Hypertens. 1998;11:1394-1404.
13. Neaton JD, Grimm RH, Prineas RJ, Stamler J, Grandits GA, Elmer PJ, Cutler JA, Flack JM, Schoenberger JA, McDonald R. Treatment of Mild Hypertension Study final results. JAMA. 1993;270:713-724.
14. Hypertension Detection and Follow-up Program Cooperative Group. Five year findings of the Hypertension Detection and Follow-up Program: prevention and reversal of left ventricular hypertrophy with antihyper-tensive drug therapy. Hypertension. 1985;7:105-112.
15. MacMahon S, Collins G, Rautaharju P, Cutler J, Neaton J, Prineas R, Crow R, Stamler J. Electrocardiographic left ventricular hypertrophy and effects of antihypertensive drug therapy in hypertensive participants in the Multiple Risk Factor Intervention Trial. Am J Cardiol. 1989;63: 202-210.
16. Schneider MP, Klingbeil AU. Delles C, Ludwig M, Kolloch RE, Krekler M, Stumpe KO, Schmieder RE. Effect of irbesartan versus atenolol on left ventricular mass and voltage: results of the CardioVascular Irbesartan Project. Hypertension. 2004;44:61-66.
17. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Dahlöf B, for the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study Investigators. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: the LIFE Study. Circulation. 2003;108: 684-690.
18. Okin PM, Devereux RB, Gerdts E, Snapinn S, Harris KE, Jern S, Kjeldsen SE, Julius S, Edelman JM, Lindholm LH, Dahlöf B. The impact of diabetes on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcomes during antihypertensive therapy: the LIFE Study. Circulation. 2006;113:1588-1596.
19. Levy D, Salomon M, D'Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation. 1994;90:1786-1793.
20. Verdecchia P, Reboldi G, Angeli F, Avanzini F, de Simone G, Pede S, Perticone F, Schillaci G, Vanuzzo D, Maggioni AP, on behalf of the HEART Survey Study Group. Prognostic value of serial electrocar-diographic voltage and repolarization changes in essential hypertension: the HEART Survey Study. Am J Hypertens. 2007;20: 997-1004.
21. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Wedel H, Lindholm LH, Dahlöf B. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and prediction of major cardiovascular events: the LIFE Study. JAMA. 2004;292:2343-2349.
22. Okin PM, Wachtell K, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Julius S, Lindholm L, Nieminen MS, Edelman JM, Dahlöf B. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation: the LIFE Study. JAMA. 2006; 296:1242-1248.
23. Okin PM, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Julius S, Edelman JM, Dahlöf B, for the LIFE Study Investigators. Reduction of electrocardiographic left ventricular hypertrophy is associated with decreased heart failure hospitalization in hypertensive patients. Ann Intern Med. 2007;147:311-319.
24. Okin PM, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Lindholm LH, Dahlöf B, for the LIFE Study Investigators. In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the LIFE Study. Hypertension. 2007;50: 984-990.
25. Gerdts E, Zabalgoitia M, Björnstad H, Svendsen TL, Devereux RB. Gender differences in systolic left ventricular function in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE Study). Am J Cardiol. 2001;87:980-983.
26. Luchner A, Bröckel U, Muscholl M, Hense H-W, Döring A, Riegger GAJ, Schunkert H. Gender-specific differences of cardiac remodeling in subjects with left ventricular dysfunction: a population-based study. Car-diovasc Res. 2002;53:720-727.
27. Hees PS, Fleg JL, Lakatta EG, Shapiro EP. Ventricular remodeling with age in normal men versus women: novel insights using three-dimensional magnetic resonance imaging. Am J Cardiol. 2002;90: 1231-1236.
28. Devereux RB, Bella JN, Palmieri V, Oberman A, Kitzman DW, Hopkins PN, Rao DC, Morgan D, Paranicas M, Fishman D, Arnett DK. Left ventricular systolic dysfunction in a biracial sample of hypertensive adults. The HyperGEN Study. Hypertension. 2001;38:417-423.
29. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Krisiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Oparil S, Wedel H, for the LIFE Study group. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
30. Okin PM, Roman MJ, Devereux RB, Kligfield P. Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products. J Am Coll Cardiol. 1995;25:417-423.
31. Sokolow M, Lyon TP. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J. 1949;37:161-186.
32. Hammond IW, Devereux RB, Alderman MH, Lutas EM, Spitzer MC, Crowley JS, Laragh JH. The prevalence and correlates of echocardio-graphic left ventricular hypertrophy among employed adults with uncomplicated hypertension. J Am Coll Cardiol. 1986;7:639-650.
33. Liao Y, Cooper RS, Mensah GA, McGee DL. Left ventricular hypertrophy has a greater impact on survival in women than in men. Circulation. 1995;92:805-810.
34. Hayward CS, Kelly RP. Gender-related differences in central arterial pressure waveform. J Am Coll Cardiol. 1997;30:1863-1871.
35. Saba PS, Roman MJ, Pini R, Spitzer M, Ganau A, Devereux RB. Relation of arterial pressure waveform to left ventricular and carotid anatomy in normotensive subjects. J Am Coll Cardiol. 1993;22:1873-1880.
36. Mitchell GF, Pfeffer MA, Fin PV, Pfeffer JM. Equipotent antihyper-tensive agents variously affect pulsatile hemodynamics and regression of cardiac hypertrophy in spontaneously hypertensive rats. Circulation. 1996;94:2923-2929.
37. Weinberg EO, Thienelt CD, Katz SE, Bartunek J, Tajima M, Rohrbach S, Douglas PS, Lorell BH. Gender differences in molecular remodeling in pressure overload hypertrophy. J Am Coll Cardiol. 1999;34:264-273.
38. Davis CE. The effect of regression to the mean in epidemiologic and clinical studies. Am J Epidemiol. 1976;104:493-498.